← Leaderboards
Andrew B West
Mayo Clinic Coll Of Med, Jacksonville
$12,449,699
Attributed
$12,449,699
Total exposure
11
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.5M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,449,699 · 11
By mechanism
R01$6,292,890 · 1
P50$1,935,871 · 1
U01$1,038,939 · 1
U18$934,403 · 1
R33$772,500 · 1
R00$721,983 · 1
Top collaborators
No co-investigators on record.
Most similar at Mayo Clinic Coll Of Med, Jacksonville
Same institution · by research overlap
- Jada M Lewis$8,224,231
Others in their field
Top investigators on “Nerve Degeneration”
- Paul S. Aisen · Cognition Therapeutics, Inc.$113,855,136
- Reisa A. Sperling · Banner Health$83,196,776
- Randall J Bateman · Washington University$83,099,227
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$76,236,227
- Jose A Luchsinger · Columbia University Health Sciences$75,117,371
- Keith A. Johnson · Banner Health$70,466,464
Research focus
Nerve DegenerationParkinson DiseaseLinkGeneticGenesPhosphotransferasesMutationPathway InteractionsLrrk2 GeneProteinsKinase InhibitorNeuronsAlpha SynucleinCellsMediatingDisease ProgressionBrainNeurodegenerative DisordersMissense MutationNeuroprotectionKnock-OutNeurotoxicityFutureDisease Susceptibility
Grant awards (46)
Mechanisms of LRRK2 Mediated Neurotoxicity$535,841
R01 · FY2025 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$519,765
R01 · FY2024 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$535,841
R01 · FY2023 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$535,841
R01 · FY2022 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$387,089
P50 · FY2022 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$535,841
R01 · FY2021 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$387,089
P50 · FY2021 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$402,500
R01 · FY2020 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$350,000
R01 · FY2020 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$314,720
P50 · FY2020 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$76,219
P50 · FY2020 · NS · contact PI
Efficacies and Pharmacodynamic Assays for LRRk2 Small-Molecule Inhibitors$401,250
R33 · FY2019 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$352,377
P50 · FY2019 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$350,000
R01 · FY2019 · NS · contact PI
Project 3: LRRK2 mediated macrophage responses in PD$418,377
P50 · FY2018 · NS · contact PI
Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors$284,399
R33 · FY2018 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$205,615
R01 · FY2018 · NS · contact PI
Exosome LRRK2 in Predicting Parkinson Disease Phenotypes$202,054
U01 · FY2018 · NS · contact PI
Exosome LRRK2 in Predicting Parkinson Disease Phenotypes$119,509
U01 · FY2018 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$115,948
R01 · FY2018 · NS · contact PI
Efficacies and Pharmacodynamic Assays for LRRk2 Small-Molecule Inhibitors$86,851
R33 · FY2018 · NS · contact PI
Exosome LRRK2 in Predicting Parkinson Disease Phenotypes$74,250
U01 · FY2018 · NS · contact PI
Exosome LRRK2 in Predicting Parkinson Disease Phenotypes$321,563
U01 · FY2017 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$321,563
R01 · FY2017 · NS · contact PI
Efficacies and Pharmacodynamic Assays for LRRK2 Small-Molecule Inhibitors$367,500
R21 · FY2016 · NS · contact PI
Exosome LRRK2 in Predicting Parkinson Disease Phenotypes$321,563
U01 · FY2016 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$321,563
R01 · FY2016 · NS · contact PI
PD-linked Susceptibilities in Myeloid-cell CNS Infiltration$96,469
P20 · FY2016 · NS · contact PI
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease$293,000
U18 · FY2015 · NS · contact PI
PD-linked Susceptibilities in Myeloid-cell CNS Infiltration$96,469
P20 · FY2015 · NS · contact PI
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease$29,198
U18 · FY2015 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$310,918
R01 · FY2014 · NS · contact PI
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease$290,070
U18 · FY2014 · NS · contact PI
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease$29,135
U18 · FY2014 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$303,067
R01 · FY2013 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$314,059
R01 · FY2012 · NS · contact PI
LRRK2 and Other Novel Exosome Proteins in Parkinson's Disease$293,000
U18 · FY2012 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$314,059
R01 · FY2011 · NS · contact PI
Mechanisms of LRRK2 Mediated Neurotoxicity$320,469
R01 · FY2010 · NS · contact PI
The Role of LRRK2 in the Pathogenesis of Parkinson's Disease$249,000
R00 · FY2010 · NS · contact PI
The Role of LRRK2 in the Pathogenesis of Parkinson's Disease$223,983
R00 · FY2009 · NS · contact PI
The Role of LRRK2 in the Pathogenesis of Parkinson's Disease$249,000
R00 · FY2008 · NS · contact PI
The Role of LRRK2 in the Pathogenesis of Parkinson's Disease$90,000
K99 · FY2007 · NS · contact PI
Therapeutic Modulation of Alpha-Synuclein Expression$23,625
F32 · FY2006 · NS · contact PI
Therapeutic Modulation of Alpha-Synuclein Expression$48,296
F32 · FY2005 · NS
The Human Parkin Promoter and NACP-Rep 1 Enhancer$30,754
F31 · FY2002 · NS